Biomark enters partnership with Sama in Tunisia

Executive Summary

• Biomark Diagnostics Inc. has signed a strategic expression of interest agreement with Sama Consulting Sarl to establish a market presence in Tunisia and potentially expand across North Africa.
• The partnership focuses on the clinical application of Biomark’s proprietary liquid biopsy platform for lung cancer detection, addressing a critical healthcare need in the region.
• A proof-of-concept trial is scheduled to begin in October 2025 to evaluate the technology's performance, accuracy, and clinical utility within the Tunisian healthcare system.

Key Details

• Parties Involved: Biomark Diagnostics Inc. and Sama Consulting Sarl.
• Agreement Type: Strategic expression of interest agreement.
• Primary Objective: Explore clinical application of Biomark’s liquid biopsy platform for lung cancer detection.
• Geographic Scope: Initial focus on Tunisia, with potential expansion to Algeria, Morocco, and seven additional countries (covering 90-plus million people).
• Trial Timeline:
  • Start Date: October 2025.
  • Completion Date: End of December 2025.
• Trial Objectives:
  • Assess technology effectiveness in the target population.
  • Advance publication of clinical data to support broader adoption.
  • Evaluate integration potential with national screening programs.
• Strategic Rationale: Leverage Sama Consulting’s local expertise and clinical connections for rapid implementation and regulatory compliance.
• Regulatory Compliance: Activities will comply with Tunisian healthcare regulations, international clinical trial standards, and data privacy requirements.
• Confidentiality: Partnership operates under comprehensive non-disclosure agreements to protect proprietary information.

Notable Quotes

• Rashid Bux, CEO of Biomark Diagnostics: "This collaboration represents a significant milestone in our mission to make advanced cancer detection accessible globally... Tunisia's commitment to improving cancer outcomes, combined with our proven liquid biopsy technology, creates an exceptional opportunity to transform early detection capabilities in that region."
• Ayoub Hitana, representing Sama Consulting: "We are excited to partner with Biomark to bring this revolutionary technology to Tunisia and later to 90-plus million across Tunisia, Algeria, Morocco and seven additional countries... this liquid biopsy technology has the potential to significantly impact patient survival rates in our region."